# Cubicin(R) for Complicated Post-surgical Wound Infections

> **NCT00651131** · PHASE4 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 69 (actual)

## Conditions studied

- Wound Infections

## Interventions

- **DRUG:** daptomycin

## Key facts

- **NCT ID:** NCT00651131
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06-01
- **Primary completion:** 2005-03-01
- **Final completion:** 2005-03-01
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** terminated due to slow enrollment
- **Last updated:** 2017-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651131, "Cubicin(R) for Complicated Post-surgical Wound Infections". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00651131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*